Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
An Update on Global Availability of COVID-19 Vaccines from Editor of The Lancet
Posted on June 11th, 2021 by Ann-Marie Roche in Pharma R&D
In the U.S., the COVID-19 vaccine roll-out has moved at a strong pace, with about half of Americans now having received at least one shot. While many of the most motivated people have been able to get vaccinated by now, plenty of others still have questions. They may wonder if the vaccines are safe in general, or safe for them personally if they have a particular condition. They may have been confronted with conflicting information about the efficacy of vaccines.
There is also the reality that, for a number of people in the U.S. and scores of people in other countries, COVID-19 vaccines are not readily available. Some Americans have found it challenging to locate nearby vaccination sites, or they may not have the necessary digital or language skills to make an appointment. Internationally, countries are struggling with everything from supply to logistics as they work to increase their vaccination rates.
Those who are already vaccinated have questions too. As people think about summer vacation plans and consider getting on airplanes for the first time in over a year, they may wonder if they are safe against the variants that have been spreading. They might also have concerns about their children who are too young to get vaccinated yet.
To help address issues like these and more, John McConnell, Editor-in-Chief of The Lancet Infectious Diseases, recently offered a webinar titled COVID-19 Vaccines: An Update on Research & Global Availability. This informative one-hour presentation explained which vaccines are available and how they work, and included discussion on the effectiveness of the vaccines, vaccine safety concerns, and what it will take to make the COVID-19 vaccines available to the world.
The webinar also highlighted ways in which the pandemic has affected the broader research landscape. This echoes a hope that Tom Williams of Professional Services expressed earlier this year when we asked Elsevier’s Life Sciences team about what they were excited to see happen in 2021: “Lessons learned on how to treat and prevent the novel virus could be used in the development of therapeutics in other disease areas, particularly around rare diseases to speed up the development and approval of effective therapeutics.”
Watch the webinar online now to learn more about how far we’ve come with vaccination efforts, and what the path forward looks like.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Director, Corporate Markets Marketing, Elsevier
- Taking on the Net Zero challenge at the government level
- Lessons learned from the Covid vaccine development process
- Accelerating synthetic chemistry with a predictive retrosynthesis solution
- Technology and empathy help make remote working a success for Elsevier
- AI Disease Modeling Supports Precision Medicine for Cancer